Immunotherapy

Overview

Immunotherapy is a type of treatment that boosts your body's natural defenses to help fight cancer.

Explore Tags

Myeloma Treatments

The following is a listing of myeloma treatments associated with this tag.

All Treatments

View all treatments in development for myeloma patients around the US.

Verified Belantamab Mafodotin
Belantamab Mafodotin

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified CAR2 Anti-CD38 A2 CAR-T Cells
CAR2 Anti-CD38 A2 CAR-T Cells

CAR2 Anti-CD38 A2 CAR-T Cells have the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity.

Verified Descartes-08
Descartes-08

Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified PVX-410
PVX-410

PVX-410 is a vaccine that can stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.

Verified RO6870810
RO6870810

RO6870810 is a BET inhibitor that is openly enrolling in a dose expansion clinical trial around the US.

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a new antibody targeting the B-cell maturation antigen (BCMA) protein and being tested in multiple myeloma.

Verified TAK-079
TAK-079

TAK-079 is a monoclonal antibody with a low-volume subcutaneous injection that targets the CD38 protein.

Verified Tinostamustine
Tinostamustine

Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).

Verified TNB-383B
TNB-383B

TNB-383B is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified Belantamab Mafodotin
Belantamab Mafodotin

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified Descartes-08
Descartes-08

Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified TAK-079
TAK-079

TAK-079 is a monoclonal antibody with a low-volume subcutaneous injection that targets the CD38 protein.

Verified Tinostamustine
Tinostamustine

Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).

Verified TNB-383B
TNB-383B

TNB-383B is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified Belantamab Mafodotin
Belantamab Mafodotin

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified CAR2 Anti-CD38 A2 CAR-T Cells
CAR2 Anti-CD38 A2 CAR-T Cells

CAR2 Anti-CD38 A2 CAR-T Cells have the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity.

Verified Descartes-08
Descartes-08

Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified RO6870810
RO6870810

RO6870810 is a BET inhibitor that is openly enrolling in a dose expansion clinical trial around the US.

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a new antibody targeting the B-cell maturation antigen (BCMA) protein and being tested in multiple myeloma.

Verified TAK-079
TAK-079

TAK-079 is a monoclonal antibody with a low-volume subcutaneous injection that targets the CD38 protein.

Verified Tinostamustine
Tinostamustine

Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).

Verified TNB-383B
TNB-383B

TNB-383B is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

SparkCures Verified Accurate, up-to-date information. Learn more


Smoldering Myeloma

The following is a listing of treatments in development for patients with Smoldering Myeloma.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified PVX-410
PVX-410

PVX-410 is a vaccine that can stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.

SparkCures Verified Accurate, up-to-date information. Learn more


Monoclonal Gammopathy of Undetermined Significance (MGUS)

The following is a listing of treatments in development for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).

Myeloma Clinical Trials

The following is a listing of myeloma clinical trials associated with this tag.

All Clinical Trials

View all active clinical trials around the US.

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

SparkCures Verified Accurate, up-to-date information. Learn more


Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Monoclonal Gammopathy of Undetermined Significance (MGUS)

The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).

Resources